The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle

The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle in Patients With Dilated Cardiomyopathy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01015144

Enrollment

Unknown

Registered

2009-11-18

Start date

2007-02-28

Completion date

2009-02-28

Last updated

2009-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated Cardiomyopathy

Keywords

atorvastatin, dilated cardiomyopathy, heart failure, inflammation

Brief summary

The aim of the study was to assess of the influence of atorvastatin on selected indicators of an inflammatory condition, function of the left ventricle and factors affecting the occurrence of undesired events like rehospitalizations and mortality in patients with dilated cardiomyopathy.

Interventions

DRUGTulip

Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients 18 years old or older * patients who signed informed consent * patients with dilated cardiomyopathy (according ESC 2007) * patients who had no significant coronary artery stenoses \>30% on cardiac catheterization

Exclusion criteria

* BP ≥140/90 lub \<90/60 * congenital heart disease * acquired valvular disease except for mitral incompetence secondary to left ventricular dilatation * New York Heart Association (NYHA) functional class IV * statin treatment * preserved hyperactivity of aminotransferases with unexplained etiology, * muscle disorders which might cause drug-induced myopathy, * uncontrolled diabetes, * liver diseases, * creatinine level \> 2 mg/dl and/or GFR\<30ml/min, * abuse of alcohol or drugs, * chronic inflammatory diseases, * pregnancy or lactation, * severe hypothyroidism, * immunosuppressive treatment, * operation or severe injury during last month * vaccination during last 3 months * heart stimulation device or implantable cardioverter defibrillator * or who didn't write conscious consent

Design outcomes

Primary

Measure	Time frame
left ventricular function	2 months

Secondary

Measure	Time frame
mortality	6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026